Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 6, 2024, at 9:15 a.m. E.T. at the New York Marriott Marquis. Senior management will engage in a fireside chat, which will be webcast live on Sarepta's investor relations website and archived for 90 days.
Sarepta focuses on developing precision genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). The company currently has over 40 programs in various stages of development, driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
Sarepta Therapeutics (NASDAQ:SRPT), un leader nella medicina genetica di precisione per le malattie rare, ha annunciato la sua partecipazione alla 22ª Conferenza Globale sulla Salute di Morgan Stanley. L'evento si svolgerà il 6 settembre 2024 alle 9:15 a.m. E.T. presso il New York Marriott Marquis. La direzione senior parteciperà a una conversazione informale, che sarà trasmessa in diretta sul sito web delle relazioni con gli investitori di Sarepta e archiviata per 90 giorni.
Sarepta si concentra sullo sviluppo di medicinali genetici di precisione per malattie rare, in particolare sulla distrofia muscolare di Duchenne (DMD) e sulle distrofie muscolari a cintura (LGMDs). L'azienda attualmente ha oltre 40 programmi in varie fasi di sviluppo, guidati dal suo motore di Medicina Genetica di Precisione multi-piattaforma nella terapia genica, RNA e editing genetico.
Sarepta Therapeutics (NASDAQ:SRPT), un líder en medicina genética de precisión para enfermedades raras, ha anunciado su participación en la 22ª Conferencia Global de Salud de Morgan Stanley. El evento tendrá lugar el 6 de septiembre de 2024 a las 9:15 a.m. E.T. en el New York Marriott Marquis. La alta dirección participará en una charla informal, que será transmitida en vivo en el sitio web de relaciones con inversores de Sarepta y archivada durante 90 días.
Sarepta se centra en el desarrollo de medicamentos genéticos de precisión para enfermedades raras, particularmente la distrofia muscular de Duchenne (DMD) y las distrofias musculares de cintura (LGMDs). La compañía actualmente tiene más de 40 programas en diversas etapas de desarrollo, impulsados por su Motor de Medicina Genética de Precisión multiplataforma en terapia génica, RNA y edición genética.
사렙타 테라퓨틱스 (NASDAQ:SRPT)는 희귀 질환을 위한 정밀 유전 의학의 선두주자로서 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. 이 행사는 2024년 9월 6일 오전 9시 15분 E.T.에 뉴욕 메리어트 마르퀴스에서 열립니다. 고위 경영진이 자리를 함께하는 대담에 참여할 예정이며, 이 대담은 실시간 웹캐스트로 사렙타의 투자자 관계 웹사이트에 방송되며, 90일간 아카이브될 것입니다.
사렙타는 희귀 질환을 위한 정밀 유전 의약품 개발에 집중하고 있으며, 특히 두센 근육 이영양증 (DMD)와 사지 띠 근육 이영양증 (LGMDs)에 초점을 맞추고 있습니다. 현재 회사는 유전자 치료, RNA 및 유전자 편집을 포함한 다중 플랫폼 정밀 유전 의학 엔진에 의해 추진되는 40개 이상의 프로그램을 다양한 개발 단계에서 진행 중입니다.
Sarepta Therapeutics (NASDAQ:SRPT), un leader dans la médecine génétique de précision pour les maladies rares, a annoncé sa participation à la 22ème Conférence Mondiale sur la Santé de Morgan Stanley. L'événement aura lieu le 6 septembre 2024 à 9h15 E.T. au New York Marriott Marquis. La haute direction participera à une discussion informelle, qui sera diffusée en direct sur le site web des relations investisseurs de Sarepta et archivée pendant 90 jours.
Sarepta se concentre sur le développement de médicaments génétiques de précision pour les maladies rares, en particulier la dystrophie musculaire de Duchenne (DMD) et les dystrophies musculaires de ceinture (LGMDs). Actuellement, l'entreprise possède plus de 40 programmes à différents stades de développement, propulsés par son moteur de médecine génétique de précision multifonctionnel en thérapie génique, ARN et édition génétique.
Sarepta Therapeutics (NASDAQ:SRPT), ein führendes Unternehmen in der präzisen genetischen Medizin für seltene Krankheiten, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley angekündigt. Die Veranstaltung findet am 6. September 2024 um 9:15 Uhr E.T. im New York Marriott Marquis statt. Die Oberleitung wird an einem informellen Gespräch teilnehmen, das live übertragen wird auf der Investor-Relations-Website von Sarepta und für 90 Tage archiviert wird.
Sarepta konzentriert sich auf die Entwicklung präziser genetischer Medikamente für seltene Krankheiten, insbesondere muskelatrophische Dystrophie vom Typ Duchenne (DMD) und Gürtelmuskeldystrophien (LGMDs). Das Unternehmen hat derzeit über 40 Programme in verschiedenen Entwicklungsstadien, die von seiner Multi-Plattform-Präzisen Genetischen Medizin-Motor in Gentherapie, RNA und Gen-Editing vorangetrieben werden.
- None.
- None.
The presentation will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240830934632/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
When and where is Sarepta Therapeutics (SRPT) presenting at the Morgan Stanley Healthcare Conference?
How can investors access Sarepta's (SRPT) presentation at the Morgan Stanley conference?
What are the main focus areas of Sarepta Therapeutics (SRPT)?
What technologies does Sarepta Therapeutics (SRPT) use in its drug development?
